Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of Quizartinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory AML~* AML for which no standard treatment is available~* ECOG Performance Status (PS) of 0 to 2~Exclusion Criteria:~* Acute Promyelocytic Leukemia~* chronic myelogenous leukemia in blast phase (BCR-ABL fusion gene positive)~* History of other malignancies within 3 years prior to enrollment, except curatively treated in-situ carcinoma, AML, or MDS.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AC220 (Type: EXPERIMENTAL): This study will follow a mCRM (modified continual reassessment method) + EWOC (Escalation with Overdose Control) design.

Based on this trial design, predict the completion outcome and termination type (if applicable).